BÜHLMANN Laboratories AG
Baselstrasse 55
CH–4124 Schönenbuch/Basel
Switzerland

Phone +41 61 487 12 00
Fax +41 61 487 12 34
support@buhlmannlabs.ch
www.buhlmannlabs.ch

Neuroimmunologia: Autoanticorpi neurali ELISA BÜHLMANN in Letteratura – 60 Riferimenti

BÜHLMANN GanglioCombi® ELISAs

- **Delmont E** et al., **2017:** Value of anti-HNK-1 Antibodies in anti-MAG Neuropathies: an analysis of 144 sera
  Poster presented at 2017 PNS Annual Meeting in Sitges (ES)

  "Gli anticorpi anti-MAG hanno buona sensibilità e specificità per rilevare la neuropatia anti-MAG. In particolare, concentrazioni di anticorpi anti-HNK-1 sono correlati all'attività della malattia "

- **Sohn SY** and **Kim J K, 2018:** Neutropenia Following Intravenous Immunoglobulin Administration in a Patiient with Multifocal Motor Neuropathy with Conduction Block. J Neurol Neurophysiol **8**:409. doi:10.4172/2155-9562.1000409

- **Legast GM et al., 2017:** Guillain-Barré and Miller Fisher Overlap Syndrome Mimicking Alimentary Botulism. J Clin Neurol **13(4):** 442-443

- **Chalah M.A.** et al, **2016:** A comparison of four commercial tests for detecting anti-ganglioside antibodies in patients with well-characterized dysimmune peripheral neuropathies.
  Poster presented at "International Congress on Autoimmunity, Leipzig (GE).

  "BÜHLMANN GanglioCombi ELISA è stato confrontato con altri test presenti sul mercato evidenziando migliori prestazioni che lo qualificano come il test di elezione per l'applicazione quotidiana nella routine clinica."

- **Cao-Lormeau V. M.** et al., **2016:** Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet **387**(10027); 1531-1539 (incl supplement).

  "BÜHLMANN GanglioCombi è stato utilizzato come test di prima scelta per identificare nuove forme post-infettive nella sindrome di Guillain-Barré come quelle associate ai Zika virus."

- **Kollewe K** et al., **2015:** Anti-Ganglioside Antibodies in Amyotrophic Lateral Sclerosis Revisited. PLoS One, **10**(4): e0125339.

  "BÜHLMANN GanglioCombi è stato utilizzato nel discriminare tra neuropatie motorie multifocali (MMN, trattabili) e patologie spesso simili nei sintomi come la sclerosi laterale amiotrofica (SLA, non trattabile).
  Questa è la più grande coorte di pazienti con SLA investigata fino ad oggi e dimostra che la frequenza di anticorpi anti-Gangliosidi non è diversa da quella dei donatori di sangue apparentemente sani."

Ulteriori fonti che citano i test BÜHLMANN GanglioCombi® ELISA / Autoanticorpi anti-GM1 ELISA

- **Herrendorff R** et al., **2017**: Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigen specific treatment option for anti-MAG neuropathy. PNAS, www.pnas.org/cgi/doi/10.1073/pnas.1619386114

- **Anaya J-M** et al., **2017**: A comprehensive analysis and immunobiology of autoimmune neurological syndromes during the Zika virus outbreak in Cúcuta, Colombia. Journal of Autoimmunity **77**: 123-138

BÜHLMANN Laboratories AG
Baselstrasse 55
CH–4124 Schönenbuch/Basel
Switzerland

Phone +41 61 487 12 00
Fax +41 61 487 12 34
support@buhlmannlabs.ch
www.buhlmannlabs.ch

- **Spatola M** et al., **2016**: Serum and CSF GQ1b antibodies in isolated ophthalmologic syndromes. Neurology **86**:1780-1784

- **Han T A** et al., **2016**: Transient Isolated Lower Bulbar Palsy with Elevated Serum Anti-GM1 and Anti-GD1b Antibodies During Aripiprazole Treatment. Pediatr Neurol **66**; 96-99.

- **Kenina V** et al., **2015**: Clinical Impact and Relevance of Antiganglioside Antibodies Test Results. Proc. Latvian Acad. Sci., Section B, 69(5): 223-227

- **Uysalol M**. et al., **2013:** A Rare Form of Guillain-Barré Syndrome: A Child Diagnosed with Anti-GD1a and Anti-GD1b Positive Pharyngeal-Cervical-Brachial Variant. Balkan Med J; **30**:337-341

- **Lei T** et al., **2012**: Anti-ganglioside antibodies were not detected in human subjects infected with or vaccinated against 2009 pandemic influenza A (H1N1) virus. Vaccine **30**: 2605-2610

- **Sharma M B** et al., **2011:** The presence of Mycoplasma pneumoniae infection and GM1 ganglioside antibodies in Guillain-Barré syndrome. I Infect Dev Countries **5**(6): 459-464

- **Mani B** et al., **2010**: The Frequency of anti-Ganglioside Antibodies in Blood Donors Compared to Control Groups and Guillain-Barré Syndrome Patients. Poster presented at DAS, Dresden (GE).

- **Wurster U** et al., **2009**: Ganglioside Antibodies in Amyotrophic Lateral Sclerosis. Poster presented at DAS, Dresden (GE).

BÜHLMANN anti-MAG Autoantibodies ELISA

- **Nobile-Orazio E** et al**., 2017**: Comparing treatment options for chronic inflammatory neuropathies and chossing the right treatment plan. 17(8): 755-765.

- **Svahn J** et al., **2018:** Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features. J Neurol Neurosurg Psychiatry **89:** 499-505.

  "I Pazienti con neuropatie anti-MAG sono stati raggruppati in diverse categorie sulla base del titolo di Anti-MAG ottenuto con il test BÜHLMANN ELISA. Nel 31.5% dei pazienti è stata monitorata la risposta clinica a Rituximab per 6 mesi e/o durante il periodo di follow-up a 7-12 mesi e correlata con un titolo di anticorpi anti-MAG ≥ 10 000 BTU."

- **Magy L.** et al., **2015**: Heterogeneity of Polyneuropathy Associated with Anti-MAG Antibodies. J Immunol Res 2015; Article ID 450391

  "BÜHLMANN anti-MAG ELISA viene definito come test quantitativo affidabile per differenziare le Neuropatie anti-MAG in tipica neuropatia anti-MAG e titoli elevati di anticorpi anti-MAG e Neuropatie CIDP-simili, risultati negativi in immunofluorescenza (IF) e bassi titoli di BTU."

- **Stork A. C. J.** et al., **2014**: Prevalence, specificity and functionality of anti-ganglioside antibodies in neuropathy associated with IgM monoclonal gammopathy. J Neuroimmunol **268**(1-2): 89-94

  "Aumento della sensibilità e discriminazione mediante la misurazione contemporanea di anticorpi anti-MAG e gangliosidi, in pazienti con neuropatie demielinizzanti e anticorpi monoclonali IgM (IgM-PNP)."

BÜHLMANN Laboratories AG
Baselstrasse 55
CH–4124 Schönenbuch/Basel
Switzerland

Phone +41 61 487 12 00
Fax +41 61 487 12 34
support@buhlmannlabs.ch
www.buhlmannlabs.ch

- **Willison H. J.** et al., **2011**: Use of antibody testing in nervous system disorders. European Handbook of Neurological Management: volume 1, 2nd edition; chapter **6**: 75-80

  "L'articolo valuta il servizio e la qualità della prestazione erogata per un test di autoanticorpi clinicamente utile in neurologia. La metodologia ELISA è una tecnica ampiamente utilizzata per la determinazione di anticorpi anti-glicolipidi e anti-MAG ed "ha una buona standardizzazione."

- **Kuijf M.** et al., **2009**: Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. Neurology **73**(9) 688-695

  "Eccellente differenziazione tra soggetti sani e pazienti con Neuropatia demielinizzante, gammopatia monoclonale con immunoglobuline M (IgM) (IgM-PNP) con area sotto la curva di 0,84"

- **Renaud S**. et al., **2003**: Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve **27**(5): 611-615

  "Il monitoraggio del trattamento con Rituximab è uno strumento importante per la gestione del paziente. Durante un trattamento efficace, la misurazione degli autoanticorpi anti-MAG mediante il test BÜHLMANN mostra una riduzione significativa che consente il follow-up dei pazienti in terapia."

Ulteriori fonti che citano il test ELISA per autoanticorpi anti-MAG di BÜHLMANN

- **Herrendorff R** et al., **2017**: Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigen specific treatment option for anti-MAG neuropathy. PNAS, www.pnas.org/cgi/doi/10.1073/pnas.1619386114

- **Baron M** et al., **2017**: Plasma exchanges for acute neurological deterioration in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) neuropathy. Journal of Neurology , **264**(6): 1132-1135

- **Doneddu P E** et al., **2017**: Deterioration of tremor after treatment with rituximab in anti-MAG neuropathy (Letter to the Editor) Journal of the Neurological Sciences **373**: 344-345

- **Gesquière-Dando A** et al., **2017**: Are electrophysiological features related to disability in patients with anti-MAG neuropathy? Clinical Neurophysiology **47:** 75-81

- **Gazzola S** et al., **2017**: Predictive factors of efficacy of rituximab in patients anti-MAG neuropathy; Journal of the Neurological Sciences **377**: 144-148

- **Fatehi F** et al., **2017:** Motor unit number index (MUNIX) in patients with anti-MAG neuropathy; Clinical Neurophysiology. doi: http://dx.org/10.1016/j.clinph.2017.04.022

- **Campagnolo M** et al., **2017**: IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy. J Neurol Neurosurg Psychiatry; 0:1-3. doi:10.1136/jnnp-2017-315736

- **Lozeron P et al., 2016:** Is distal motor and/or sensory demyelinatoion a distinctive feature of anti-MAG neuropathy? Journal of Neurology **263:** 1761-1770

- **Gomez A and Hoffman J E**, **2016**: Anti Myelin-Associated-Glycoprotein Antibody Peripheral Neuropathy Response to Combination Chemoimmunotherapy With Bendamustine/Rituximab in a Patient With Biclonal IgM κ and IgM λ: Case Report and Review of the Literature. Clin Lymphoma Myeloma Leuk **16**(7): e101-108.

- **Stork A C J** et al., **2016**: Classical and lectin complement pathway activity in polyneuropathy associated with IgM monoclonal gammopathy. J Neuroimmunol **290**: 76-79

- **Ferfoglia R I** et al., **2016**: Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study. J Peripher Nerv Syst **21**(1): 10-14

- **Campagnolo M** et al., **2015**: Polyneuropathy with anti-sulfatide and anti-MAG antibodies: clinical, neurophysiological, pathological features and response to treatment. J Neuroimmunol **281**: 1-4

- **Stork A C J** et al., **2014**: Clinical phenotype of patients with neuropathy associated with monoclonal gammopathy: a comparative study and a review of the literature. J Neurol **261**(7): 1389-1404

- **Sala E** et al., **2014**: Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy. J Neurol Sci **345**(1-2):224-227

- **Bridel C** et al., **2014**: Multifocal motor neuropathy with high titers of anti-MAG antibodies. J Peripher Nerv Syst **19**(2): 180-182

- **Hospital M A** et al., **2013**: Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients. Haematologica **98**(12): e155-157

- **Piscosquito G** et al., **2013**: Coexistence of Charcot-Marie-Tooth disease type 1A and anti-MAG neuropathy. J Peripher Nerv Syst **18**(2): 185-188

- **Stork A C J** et al., **2013**: Rapid worsening of IgM anti-MAG demyelinating polyneuropathy during rituximab treatment. J Peripher Nerv Syst **18**(2): 189-192

- **Pihan M** et al., **2012**: [Neuropathies associated with monoclonal IgM anti-MAG antibodies]. Rev Med Interne; **33**(12): 686-692

- **Maurer M A** et al., **2012**: Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. J Clin Invest **122**(4):1393-1402

- **Mostafa G A** et al., **2012**: Reduced serum concentrations of 25-hydroxy vitamin D in children with autism: relation to autoimmunity. J Neuroinflammation **17**(9): 201

- **Zara G** et al., **2011**: Neurophysiological and clinical responses to rituximab in patients with anti-MAG polyneuropathy. Clin Neurophysiol **122**(12): 2518-2522

- **Matà S** et al., **2011**: Anti-myelin associated glycoprotein antibodies recognize HNK-1 epitope on CNS. J Neuroimmunol **236**(1-2): 99-105

- **Larue S** et al., **2011**: Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. Eur J Neurol **18**(6): 899-905

- **Matà S** et al., **2011**: IgM monoclonal gammopathy-associated neuropathies with different IgM specificity. Eur J Neurol **18**(8): 1067-1073

- **Jurici S** et al., **2011**: An Autopsy Case of Amyotrophic Lateral Sclerosis with Waldenstrom Macroglobulinemia and Anti-MAG Gammopathy. Case Rep Neurol **3**(3): 294-400

- **Gruson B** et al., **2011**: Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy. J Peripher Nerv Syst **16**(3): 180-185.

- **Théaudin M** et al., **2011**: Short and long-term effect of IVIg in demyelinating neuropathy associated with MGUS, experience of a monocentric study, Rev Neurol (Paris) **167**(12): 897-904

- **Delmont E** et al., **2011**: Treatment with rituximab in patients with polyneuropathy with anti-MAG antibodies. J Neurol **258**(9): 1717-1719

- **Jaskowsky T D** et al., **2007**: Further comparisons of assays for detecting MAG IgM autoantibodies. J Neuroimmunol **187**(1-2): 175-178

- **Steck A** et al., **2006**: Anti-myelin-associated glycoprotein neuropathy. Curr Opin Neurol; **19**(5): 458-463

- **Renaud S** et al., **2006**: High-dose rituximab and anti-MAG-associated polyneuropathy. Neurology **66**(5): 742-744

- **Caudie C** et al., **2006**: [Diagnostic value of autoantibodies to MAG by ELISA Bühlmann in 117 immune-mediated peripheral neuropathies associated with monoclonal IgM to SGPG/SGLPG]. Ann Biol Clin **64**(4): 353-359

- **Kvarnström M** et al., **2002**: Myelin protein P0-specific IgM producing monoclonal B cell lines were established from polyneuropathy patients with monoclonal gammopathy of undetermined significance (MGUS). Clin Exp Immunol **127**(2): 255-262

BÜHLMANN anti-SGPG Autoantibodies ELISA

- **Herrendorff R** et al., **2017**: Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigen specific treatment option for anti-MAG neuropathy. PNAS, www.pnas.org/cgi/doi/10.1073/pnas.1619386114

- **Caudie C** et al., **2007: [**Diagnostic value of the anti-IgM SGPG Elisa (BÜHLMANN Laboratories AG) in 147 sera with a monoclonal IgM anti-MAG/SGPG antibody-associated neuropathy]. Ann Biol Clin (Paris) 65(4): 369-375

> "Il test per autoanticorpi anti-SGPG ELISA di BÜHLMANN si è rivelato un test commerciale molto affidabile. E' un test per la rilevazione di neuropatie demielinizzanti mediate da anticorpi MAG / SGPG senza difficoltà tecniche ed eccellenti sensibilità (0,98) e specificità (0,98). I titoli anticorpali di Anti-SGPG risultano validi sia per la gestione che per il follow - up di Neuropatie trattate con Rituximab."

- **Bridel C** et al., **2014**: Multifocal motor neuropathy with high titres of anti-MAG antibodies. J Peripher Nerv Syst **19**(2): 180-182

- **Kuijf M** et al., **2009**: Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. Neurology **73**(9): 688-695